BUSINESS

Daiichi Sankyo Takes Aim at Top Spot in Japan Ethical Drug Market: Next President

February 27, 2017

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Sunao Manabe, incoming president of Daiichi Sankyo, has expressed his eagerness to capture the top spot in Japan ethical drug sales in the near future by bolstering the company’s anticoagulant Lixiana (edoxaban) and other major products. “We want to be…

To read the full story

Daiichi Sankyo Taps EVP Manabe as Next President
February 1, 2017

BUSINESS

DMD Gene Therapy Elevidys Hits Japan Market at Record Price
February 20, 2026
Bayer Eyes Kerendia as Standard Therapy for CKM Syndrome
February 20, 2026
Enhertu Accepted for EU Review in Post-Neoadjuvant HER2 Breast Cancer
February 20, 2026
SymBio Receives Grant for Antiviral Brincidofovir
February 20, 2026
Over 40% of Breast Surgeons Largely Unaware of Clinical Trials: Survey
February 20, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…

COMMENTARY

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?

By Hayate Horiguchi

Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…